click below
click below
Normal Size Small Size show me how
CNS Drugs
| Question | Answer |
|---|---|
| Class of drugs for anxietic disorders (2) & examples | Benzodiazepines eg. Midazolam, lorazepam and diazepam. Non- benzodiazepines eg. Zolpidem |
| Benzodiazepine: Mode of action | Binds to specific sites in the CNS and potentiates GABA (an inhibitory neurotransmitter) actions by increasing the frequency of Cl channel opening. This moderates neural transmission and reduces anxiety. It is GABA dependent. |
| Benzodiazepine: Characteristics | It has short acting (eg. midazolam, which is cleared from the body within 2-4h), intermediate (eg. lorazepam which is cleared in 8h) and long acting (diazepam, cleared in 16h) drugs. |
| Benzodiazepine: Characteristics | It has short acting (eg. midazolam, which is cleared from the body within 2-4h), intermediate (eg. lorazepam which is cleared in 8h) and long acting (diazepam, cleared in 16h) drugs. |
| Benzodiazepine: Uses | Anxiety disorders, sedation before gastroscopy. |
| Benzodiazepine: Uses | Anxiety disorders, sedation before gastroscopy. |
| Benzodiazepine: Toxicity | Drowsiness, increased reaction time, decreased motor skills, anterograde amnesia. Affects breathing and BP. Paradoxical effects are rare and can include irritability, garrulousness, hallucination. Tolerance, dependence, withdrawal, neonatal toxicity. |
| Non-benzodiazepine hypnotics: MOA | Same as benzodiazepine |
| Non-benzodiazepine hypnotics: Toxicity | Withdrawal anxiety, abuse potential, tolerance, dependence. |
| Class of drugs for insomnia: | Anti histamines (mostly 1st generation) |
| Anti-histamines: MOA | Binds to H1 receptor, eliminating histamine actions by competitive inhibition. |
| Class of drugs for insomnia: | Anti histamines (mostly 1st generation) |
| Anti-histamines: Uses | Used to relieve nasal congestion, allergic response and hypnotic agents. |
| Anti-histamines: MOA | Binds to H1 receptor, eliminating histamine actions by competitive inhibition. |
| Anti-histamines: Toxicity | Dry mouth, increased appetite (can lead to obesity), blurring of vision and constipation. |
| Classes of drugs for depression: (2) | Selective serotonin re-uptake inhibitors, eg. Fluoxetine, paroxetine. Tricyclic anti-depressants eg. Imipramine, amitriptyline. |
| SSRIs: MOA | Inhibits serotonin re-uptake transporter, enabling neurotransmitter present at synapse to continue acting on post-synaptic neurons. This corrects the monoamine deficiency. |
| SSRIs: Toxicity | Anxiety, weight gain/loss (depending if the person eats alot or too little when he is depressed), headache, nausea, sexual dysfunction (decreased libido and anorgasmia) |
| TCAs: MOA | Inhibits both norepinephrine and serotonin re-uptake transporters. |
| TCAs:Toxicity | Used to be first line drug, but overtaken by SSRIs due to cardiac effects. Eg. Tachycardia, arrythmias, postural hypertension. Causes anti-cholinergic effects eg. constipation, blurring of vision, dry mouth, urinary retention, sedation and fatigue. |
| TCAs: MOA | Inhibits both norepinephrine and serotonin re-uptake transporters. |
| TCAs:Toxicity | Used to be first line drug, but overtaken by SSRIs due to cardiac effects. Eg. Tachycardia, arrythmias, postural hypertension. Causes anti-cholinergic effects eg. constipation, blurring of vision, dry mouth, urinary retention, sedation and fatigue. |